Table 1:
Three-Year Survival Probabilities with 95% CIs for Various Malignant and Non-Malignant Disorders, 2010–2019
| Disorder | Matched Related Donor (MRD), % | Unrelated Donor (URD), % | |||||
|---|---|---|---|---|---|---|---|
| CR1 | CR2+ | Relapse/Never in CR | CR1 | CR2 | Relapse/Never in CR | ||
| AML | Pediatric | 69 (63–74) | 66 (57–74) | 29 (18–41) | 60 (56–65) | 63 (57–69) | 34 (26–43) |
| AYA | 69 (65–72) | 69 (63–75) | 41 (35–47) | 65 (63–68) | 59 (55–63) | 32 (28–37) | |
| Adult | 58 (57–60) | 53 (50–56) | 32 (30–34) | 55 (54–57) | 52 (50–54) | 31 (29–32) | |
| ALL | Pediatric | 79 (73–83) | 71 (66–75) | 59 (42–75) | 75 (70–79) | 63 (59–67) | 62 (48–75) |
| AYA | 71(68–74) | 55 (49–60) | 37 (28–47) | 69 (66–72) | 51 (47–55) | 38 (30–46) | |
| Adult | 63 (61–66) | 45 (41–50) | 36 (30–43) | 63 (61–65) | 44 (40–47) | 36 (31–42) | |
| Early | Advanced | Early | Advanced | ||||
| MDS | 54 (50–58) | 46 (44–49) | 50 (47–52) | 44 (43–46) | |||
| Chronic | Accelerated | Blast | Chronic | Accelerated | Blast | ||
| CML | 66 (60–71) | 47 (35–59) | 34 (21–48) | 62 (58–66) | 54 (45–64) | 35 (24–47) | |
| CLL | 64 (59–68) | 58 (55–61) | |||||
| Myelofibrosis | 65 (61–69) | 56 (53–59) | |||||
| Other MPN | 57 (52–62) | 57 (53–61) | |||||
| SAA | Pediatric | 98 (96–99) | 86 (83–89) | ||||
| Adult | 84 (81–87) | 75 (71–78) | |||||
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; CLL, chronic lymphoblastic leukemia; CML, chronic myelogenous leukemia; SAA, severe aplastic anemia